Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Bayer Clinical Study Identification Number or study title by entering text and clicking search.

 

9 found

Click the study title to find more information about the study.

BAYER-14371
Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal female adolescents under 18 years of age for 1 year, and an optional 2-year extension phase

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 14371, Sponsor: Bayer
BAYER-91775
Multi-center, open label, single arm study to assess efficacy, safety, bleeding pattern and pharmacokinetics of the ultra low dose levonorgestrel intrauterine contraceptive system (LCS) for a maximum of 3 years in women 18 to 40 years of age

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 91775, Sponsor: Bayer
BAYER-90870
A Multicenter, Open-Label, Non-Randomized Study of SH G 00650 A (Levonorgestrel Intrauterine System) in Parous Women Seeking Contraception to Evaluate its Efficacy, Safety, and Pharmacokinetic Profile When Inserted for 12 months

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 90870, Sponsor: Bayer
BAYER-91412
Multi-center, open, randomized, dose finding phase II study to investigate ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing different amounts of levonorgestrel compared to MIRENA in nulliparous and parous women in need of contraception.

Medicine: Levonorgestrel, Condition: Contraception, Phase: 2, Clinical Study ID: 91412, Sponsor: Bayer
BAYER-13362
Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day initial in vitro release rate (LCS12) in comparison to a combined oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone (Yasmin®) in young women (18-29 years) over 18 months of use

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 13362, Sponsor: Bayer
BAYER-13363
Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonorgestrel subdermal implant over 12 months of use in women 18 to 35 years of age

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 13363, Sponsor: Bayer
BAYER-91665
Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age and an extension phase of the 16µg/24h dose group (LCS16 arm) up to 5 years

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: 91665, Sponsor: Bayer
*BAYER-B078
Five-year Clinical Performance of the New Formulation of the Levonorgestrel Intrauterine System and Serum Levonorgestrel Concentration with the New Formulation Compared to That with the Original One.

Medicine: Levonorgestrel, Condition: Contraception, Phase: 3, Clinical Study ID: B078, Sponsor: Bayer
BAYER-15982
A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib (RESORCE)

Medicine: Regorafenib, Condition: Hepatocellular carcinoma, Phase: 3, Clinical Study ID: 15982, Sponsor: Bayer.
First Previous 1 Next Last